Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13576815 | 1.00 | PNP (0.55) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL31359571 | 1.00 | PNP (0.55) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL13528511 | 0.87 | ADORA1 (0.64) | PDE4DPDE3ASMN1; SMN2P2RY1ADORA1 | |
| SCHEMBL3502762 | 0.87 | ADORA1 (0.64) | PDE4DPDE3ASMN1; SMN2P2RY1ADORA1 | |
| SCHEMBL29547295 | 0.87 | ADORA1 (0.64) | PDE4DPDE3ASMN1; SMN2P2RY1ADORA1 | |
| SCHEMBL8970868 | 0.86 | LMNA (0.58) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL22300667 | 0.86 | LMNA (0.58) | PNPLMNATP53HTTPDE4D | |
| Phosphoric Acid SCHEMBL4820778 | 0.85 | PNP (0.72) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL9548885 | 0.85 | PNP (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL26800650 | 0.85 | PNP (0.54) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ADAR, ADA, NUDT1 | PNP 15/4885LMNA 2117/4885TP53 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.